Literature DB >> 2015821

Structure determination of the glycans of human-serum alpha 1-antichymotrypsin using 1H-NMR spectroscopy and deglycosylation by N-glycanase.

A Laine1, E Hachulla, G Strecker, J C Michalski, J M Wieruszeski.   

Abstract

alpha 1-Antichymotrypsin purified from normal human serum was separated by affinity chromatography into th ree microheterogeneous forms on a concanavalin-A-Sepharose column: a pass-through (peak 1), a retarded (peak 2) and a bound form (peaks 3 + 4). For each form the asparagine-linked carbohydrate chains were liberated as oligosaccharides by hydrazinolysis, submitted to reduction with NaBH4 after re-N-acetylation and further separated by affinity chromatography on a concanavalin-A-Sepharose column. The complete primary structure of the glycans was determined by high-resolution 1H-NMR spectroscopy. The results indicated the presence of disialyl diantennary and of trisialyl triantennary type glycanic structures, the latter being accompanied by traces of disialylated triantennary oligosaccharide. The N-glycanase was used for the deglycosylation of the unfractionated alpha 1-antichymotrypsin; the successive removal of the N-linked complex-type oligosaccharide side chains of alpha 1-antichymotrypsin was studied in the presence of detergents. From these experiments it is concluded that alpha 1-antichymotrypsin carries four oligosaccharide side chains. Moreover our results show that the peak 1 contains four triantennary glycans, the peak 2 three triantennary and one diantennary glycans while the bound peaks 3 + 4 possess, on average, about one triantennary and three diantennary glycans per molecule. Since we showed that the peak 4 contains mostly diantennary glycans, it can be deduced that in peak 3 there are molecules carrying two triantennary and two diantennary glycans and others carrying one triantennary and three diantennary glycans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015821     DOI: 10.1111/j.1432-1033.1991.tb15901.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Studies on the interaction between hyaluronan and a rat colon cancer cell line.

Authors:  C Samuelsson; S Gustafson
Journal:  Glycoconj J       Date:  1998-02       Impact factor: 2.916

2.  Stimulatory effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells.

Authors:  J Cichy; J Potempa; R K Chawla; J Travis
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

3.  Isolation and characterization of a sialo-glycopeptide from buffalo colostrum.

Authors:  H S Aparna; P V Salimath
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

4.  Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in alpha3-fucosylation of alpha1-acid glycoprotein.

Authors:  E C Havenaar; J S Axford; E C Brinkman-van der Linden; A Alavi; E C Van Ommen; B van het Hof; T Spector; A Mackiewicz; W Van Dijk
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

5.  Altered glycosylation profile of purified plasma ACT from Alzheimer's disease.

Authors:  Manuela Ianni; Marcella Manerba; Giuseppina Di Stefano; Elisa Porcellini; Martina Chiappelli; Ilaria Carbone; Federico Licastro
Journal:  Immun Ageing       Date:  2010-12-16       Impact factor: 6.400

6.  Glycoproteoform Profiles of Individual Patients' Plasma Alpha-1-Antichymotrypsin are Unique and Extensively Remodeled Following a Septic Episode.

Authors:  Tomislav Čaval; Yu-Hsien Lin; Meri Varkila; Karli R Reiding; Marc J M Bonten; Olaf L Cremer; Vojtech Franc; Albert J R Heck
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

7.  In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease.

Authors:  Zhengwei Chen; Qinying Yu; Qing Yu; Jillian Johnson; Richard Shipman; Xiaofang Zhong; Junfeng Huang; Sanjay Asthana; Cynthia Carlsson; Ozioma Okonkwo; Lingjun Li
Journal:  Mol Cell Proteomics       Date:  2021-04-20       Impact factor: 5.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.